Literature DB >> 14566705

eIF2B-related disorders: antenatal onset and involvement of multiple organs.

Marjo S van der Knaap1, Carola G M van Berkel, Jochen Herms, Rudy van Coster, Martina Baethmann, Sakkubai Naidu, Eugen Boltshauser, Michèl A A P Willemsen, Barbara Plecko, Georg F Hoffmann, Christopher G Proud, Gert C Scheper, Jan C Pronk.   

Abstract

Leukoencephalopathy with vanishing white matter, also called "childhood ataxia with central nervous system hypomyelination," is the first human disease related to mutations in any of the five genes encoding subunits of eukaryotic initiation factor eIF2B or any translation factor at all. eIF2B is essential in all cells of the body for protein synthesis and the regulation of this protein synthesis under different stress conditions. It is surprising that mutations in the eIF2B genes have been reported to lead to abnormalities of the white matter of the brain only, although it has been shown recently that ovarian failure may accompany the leukoencephalopathy. Another surprising observation is that the onset of the disease varies from early childhood to adulthood, with the exception of Cree leukoencephalopathy, a disease related to a particular mutation in one of the eIF2B genes, which invariably has its onset within the first year of life. We analyzed the eIF2B genes of nine patients with an antenatal- or early-infantile-onset encephalopathy and an early demise and found mutations in eight of the patients. In addition to signs of a serious encephalopathy, we found oligohydramnios, intrauterine growth retardation, cataracts, pancreatitis, hepatosplenomegaly, hypoplasia of the kidneys, and ovarian dysgenesis. Until now, no evidence had been found for a genotype-phenotype correlation, but the consistently severe phenotype in affected siblings among our patients and in Cree encephalopathy patients suggests an influence of the genotype on the phenotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14566705      PMCID: PMC1180499          DOI: 10.1086/379524

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  30 in total

Review 1.  Mammalian stress response: cell physiology, structure/function of stress proteins, and implications for medicine and disease.

Authors:  W J Welch
Journal:  Physiol Rev       Date:  1992-10       Impact factor: 37.312

Review 2.  Regulation of translation initiation factors by signal transduction.

Authors:  M Kleijn; G C Scheper; H O Voorma; A A Thomas
Journal:  Eur J Biochem       Date:  1998-05-01

3.  Inactivation of eIF2B and phosphorylation of PHAS-I in heat-shocked rat hepatoma cells.

Authors:  G C Scheper; J Mulder; M Kleijn; H O Voorma; A A Thomas; R van Wijk
Journal:  J Biol Chem       Date:  1997-10-24       Impact factor: 5.157

4.  Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase.

Authors:  H P Harding; Y Zhang; D Ron
Journal:  Nature       Date:  1999-01-21       Impact factor: 49.962

5.  A new leukoencephalopathy with vanishing white matter.

Authors:  M S van der Knaap; P G Barth; F J Gabreëls; E Franzoni; J H Begeer; H Stroink; J J Rotteveel; J Valk
Journal:  Neurology       Date:  1997-04       Impact factor: 9.910

6.  Defining and categorizing leukoencephalopathies of unknown origin: MR imaging approach.

Authors:  M S van der Knaap; S N Breiter; S Naidu; A A Hart; J Valk
Journal:  Radiology       Date:  1999-10       Impact factor: 11.105

7.  Phenotypic variation in leukoencephalopathy with vanishing white matter.

Authors:  M S van der Knaap; W Kamphorst; P G Barth; C L Kraaijeveld; E Gut; J Valk
Journal:  Neurology       Date:  1998-08       Impact factor: 9.910

8.  Diffuse white matter disease in three children: an encephalopathy with unique features on magnetic resonance imaging and proton magnetic resonance spectroscopy.

Authors:  F Hanefeld; U Holzbach; B Kruse; E Wilichowski; H J Christen; J Frahm
Journal:  Neuropediatrics       Date:  1993-10       Impact factor: 1.947

9.  Use of monoclonal antibodies to study the structure and function of eukaryotic protein synthesis initiation factor eIF-2B.

Authors:  S Oldfield; B L Jones; D Tanton; C G Proud
Journal:  Eur J Biochem       Date:  1994-04-01

10.  Childhood ataxia with diffuse central nervous system hypomyelination.

Authors:  R Schiffmann; J R Moller; B D Trapp; H H Shih; R G Farrer; D A Katz; J R Alger; C C Parker; P E Hauer; C R Kaneski
Journal:  Ann Neurol       Date:  1994-03       Impact factor: 10.422

View more
  31 in total

1.  Clinical and neuroimaging findings of Cree leukodystrophy: a retrospective case series.

Authors:  S Harder; A Gourgaris; E Frangou; K Hopp; R Huntsman; N Lowry; S Seshia; E Lemire; C Robinson; J Tynan
Journal:  AJNR Am J Neuroradiol       Date:  2010-04-29       Impact factor: 3.825

2.  Heightened stress response in primary fibroblasts expressing mutant eIF2B genes from CACH/VWM leukodystrophy patients.

Authors:  Liraz Kantor; Heather P Harding; David Ron; Raphael Schiffmann; Christine R Kaneski; Scot R Kimball; Orna Elroy-Stein
Journal:  Hum Genet       Date:  2005-10-28       Impact factor: 4.132

3.  Astrocytes are central in the pathomechanisms of vanishing white matter.

Authors:  Stephanie Dooves; Marianna Bugiani; Nienke L Postma; Emiel Polder; Niels Land; Stephen T Horan; Anne-Lieke F van Deijk; Aleid van de Kreeke; Gerbren Jacobs; Caroline Vuong; Jan Klooster; Maarten Kamermans; Joke Wortel; Maarten Loos; Lisanne E Wisse; Gert C Scheper; Truus E M Abbink; Vivi M Heine; Marjo S van der Knaap
Journal:  J Clin Invest       Date:  2016-03-14       Impact factor: 14.808

4.  Evidence of placental translation inhibition and endoplasmic reticulum stress in the etiology of human intrauterine growth restriction.

Authors:  Hong-wa Yung; Stefania Calabrese; Debby Hynx; Brian A Hemmings; Irene Cetin; D Stephen Charnock-Jones; Graham J Burton
Journal:  Am J Pathol       Date:  2008-06-26       Impact factor: 4.307

5.  An autopsy case of infantile-onset vanishing white matter disease related to an EIF2B2 mutation (V85E) in a hemizygous region.

Authors:  Yukiko Hata; Koshi Kinoshita; Kazushi Miya; Keiichi Hirono; Fukiko Ichida; Koji Yoshida; Naoki Nishida
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

6.  De novo EIF2AK1 and EIF2AK2 Variants Are Associated with Developmental Delay, Leukoencephalopathy, and Neurologic Decompensation.

Authors:  Dongxue Mao; Chloe M Reuter; Maura R Z Ruzhnikov; Anita E Beck; Emily G Farrow; Lisa T Emrick; Jill A Rosenfeld; Katherine M Mackenzie; Laurie Robak; Matthew T Wheeler; Lindsay C Burrage; Mahim Jain; Pengfei Liu; Daniel Calame; Sébastien Küry; Martin Sillesen; Klaus Schmitz-Abe; Davide Tonduti; Luigina Spaccini; Maria Iascone; Casie A Genetti; Mary K Koenig; Madeline Graf; Alyssa Tran; Mercedes Alejandro; Brendan H Lee; Isabelle Thiffault; Pankaj B Agrawal; Jonathan A Bernstein; Hugo J Bellen; Hsiao-Tuan Chao
Journal:  Am J Hum Genet       Date:  2020-03-19       Impact factor: 11.025

7.  Sensitivity and specificity of decreased CSF asialotransferrin for eIF2B-related disorder.

Authors:  A Vanderver; Y Hathout; J Maletkovic; E S Gordon; M Mintz; M Timmons; E P Hoffman; L Horzinski; F Niel; A Fogli; O Boespflug-Tanguy; R Schiffmann
Journal:  Neurology       Date:  2008-06-03       Impact factor: 9.910

8.  Role of Saccharomyces cerevisiae TAN1 (tRNA acetyltransferase) in eukaryotic initiation factor 2B (eIF2B)-mediated translation control and stress response.

Authors:  Sonum Sharma; Anuradha Sourirajan; Kamal Dev
Journal:  3 Biotech       Date:  2017-07-04       Impact factor: 2.406

9.  Vanishing white matter disease with different faces.

Authors:  Gülay Güngör; Olcay Güngör; Seda Çakmaklı; Hülya Maraş Genç; Hülya İnce; Gözde Yeşil; Cengiz Dilber; Kürşad Aydın
Journal:  Childs Nerv Syst       Date:  2019-08-05       Impact factor: 1.475

10.  Eukaryotic initiation factor 2B (eIF2B) GEF activity as a diagnostic tool for EIF2B-related disorders.

Authors:  Laetitia Horzinski; Aurélia Huyghe; Marie-Céleste Cardoso; Céline Gonthier; Lemlih Ouchchane; Raphael Schiffmann; Pierre Blanc; Odile Boespflug-Tanguy; Anne Fogli
Journal:  PLoS One       Date:  2009-12-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.